Celebrex ® — Net Sales
Viatris Celebrex ® — Net Sales increased by 1.4% to $67.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $63.40M to $67.10M. Over 4 years (FY 2021 to FY 2025), Celebrex ® — Net Sales shows a downward trend with a -5.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests strong market demand or successful lifecycle management, while a decrease often signals increased generic competition, loss of patent exclusivity, or declining clinical preference.
Detailed definition
This metric represents the total revenue generated from the sale of the Celebrex brand, a non-steroidal anti-inflammator...
Peer comparison
Comparable to revenue metrics for mature, branded pharmaceutical products at other global drug manufacturers, often evaluated against the backdrop of patent cliffs and generic erosion.
vtrs_segment_celebrex_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $82.30M | $86.00M | $87.10M | $85.20M | $85.90M | $82.20M | $84.70M | $88.80M | $82.00M | $84.70M | $75.10M | $72.20M | $72.20M | $74.10M | $67.10M | $63.40M | $70.00M | $73.30M | $66.20M | $67.10M |
| QoQ Change | — | +4.5% | +1.3% | -2.2% | +0.8% | -4.3% | +3.0% | +4.8% | -7.7% | +3.3% | -11.3% | -3.9% | +0.0% | +2.6% | -9.4% | -5.5% | +10.4% | +4.7% | -9.7% | +1.4% |
| YoY Change | — | — | — | — | +4.4% | -4.4% | -2.8% | +4.2% | -4.5% | +3.0% | -11.3% | -18.7% | -12.0% | -12.5% | -10.7% | -12.2% | -3.0% | -1.1% | -1.3% | +5.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's celebrex ® — net sales?
- Viatris (VTRS) reported celebrex ® — net sales of $67.10M in Q1 2026.
- How has Viatris's celebrex ® — net sales changed year-over-year?
- Viatris's celebrex ® — net sales increased by 5.8% year-over-year, from $63.40M to $67.10M.
- What is the long-term trend for Viatris's celebrex ® — net sales?
- Over 4 years (2021 to 2025), Viatris's celebrex ® — net sales has grown at a -5.7% compound annual growth rate (CAGR), from $344.40M to $272.90M.
- What does celebrex ® — net sales mean?
- The total revenue earned from selling the Celebrex pharmaceutical product.